Publicações

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Hiv Type 1-Infected Patients: Week 48 Results

AuthID
P-004-ZWA

Author(s)

Gallant, JE

Koenig, E

Andrade Villanueva, J

Chetchotisakd, P

DeJesus, E

Antunes, F

Arasteh, K

Moyle, G

Rizzardini, G

Fehr, J

Liu, YP

Zhong, LJ

Callebaut, C

Szwarcberg, J

Rhee, MS

Cheng, AK

Tipo de Documento

Article

Year published

2013

Publicado

in JOURNAL OF INFECTIOUS DISEASES, ISSN: 0022-1899

Volume: 208, Número: 1, Páginas: 32-39 (8)

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1093/infdis/jit122

Pubmed: 23532097

SCOPUS: 2-s2.0-84878525908

Wos: WOS:000319830300007

Source Identifiers

ISSN: 0022-1899

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Hiv Type 1-Infected Patients: Week 48 Results

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Hiv Type 1-Infected Patients: Week 48 Results

Links Úteis

Ajuda